tetano
Editor, Senior Moderator
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):158-169.
[Pharmaceutical care for severe and critically ill patients with COVID-19].
[Article in Chinese]
Jiang S[SUP]1[/SUP], Li L[SUP]1[/SUP], Ru R[SUP]2[/SUP], Zhang C[SUP]3[/SUP], Rao Y[SUP]1[/SUP], Lin B[SUP]4[/SUP], Wang R[SUP]1[/SUP], Chen N[SUP]1[/SUP], Wang X[SUP]1[/SUP], Cai H[SUP]1[/SUP], Sheng J[SUP]1[/SUP], Zhou J[SUP]1[/SUP], Lu X[SUP]1[/SUP], Qiu Y[SUP]1[/SUP].
Author information
Abstract
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
PMID:32391659
[Pharmaceutical care for severe and critically ill patients with COVID-19].
[Article in Chinese]
Jiang S[SUP]1[/SUP], Li L[SUP]1[/SUP], Ru R[SUP]2[/SUP], Zhang C[SUP]3[/SUP], Rao Y[SUP]1[/SUP], Lin B[SUP]4[/SUP], Wang R[SUP]1[/SUP], Chen N[SUP]1[/SUP], Wang X[SUP]1[/SUP], Cai H[SUP]1[/SUP], Sheng J[SUP]1[/SUP], Zhou J[SUP]1[/SUP], Lu X[SUP]1[/SUP], Qiu Y[SUP]1[/SUP].
Author information
Abstract
Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on Diagnosis and treatment of novel coronavirus pneumonia (trial version 6), and Management of COVID-19: the Zhejiang experience, we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.
PMID:32391659